Vmn2r3 can impede the protein's function through various mechanisms that disrupt its intracellular trafficking and membrane expression. Chloroquine and Bafilomycin A1, for instance, target endosomal acidification, a process crucial for receptor trafficking to the plasma membrane. By inhibiting V-ATPases, Bafilomycin A1 directly prevents the acidification of endosomes, which is a prerequisite for the proper trafficking of Vmn2r3. Similarly, Chloroquine raises the pH in intracellular vacuoles, which hampers the trafficking and functional presentation of Vmn2r3 on the cell surface. Dynasore, another chemical inhibitor, hinders the GTPase activity of dynamin, a protein essential for the scission of clathrin-coated vesicles during endocytosis. This action disrupts the endocytic recycling of Vmn2r3, essential for its resensitization and sustained signaling. Genistein and Emodin inhibit tyrosine kinases that phosphorylate key proteins involved in endocytosis and trafficking, thereby preventing the recycling of Vmn2r3 to the cell surface and impeding its signaling capabilities.
Monensin, by disrupting Golgi function, impedes the post-translational modification of Vmn2r3, which is necessary for its correct folding and trafficking to the cell membrane. The disruption of such processes curtails the functional expression of Vmn2r3. Filipin III, by disturbing cholesterol-rich lipid rafts within the cell membrane, can alter the microdomains necessary for the correct localization and function of Vmn2r3, thus inhibiting its activity. The cytoskeleton plays a pivotal role in the intracellular transport and localization of membrane proteins, and agents like Cytochalasin D and Latrunculin B inhibit the polymerization of actin, thus hampering the cytoskeletal dynamics required for Vmn2r3 trafficking. Nocodazole, a microtubule-disrupting agent, similarly affects intracellular transport processes that are vital for the proper trafficking of Vmn2r3. Finally, Gö6976, by inhibiting protein kinase C, can alter the phosphorylation state of proteins involved in the intracellular signaling and membrane targeting of Vmn2r3, leading to a reduction in its functional presence at the cell surface. Each of these chemicals, through their specific actions on the cellular pathways, directly contributes to the functional inhibition of Vmn2r3.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is known to inhibit endosomal acidification, which would inhibit Vmn2r3 by preventing proper receptor trafficking to the membrane, ultimately reducing receptor function at the cell surface. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 specifically inhibits V-ATPases, which would prevent endosome acidification, a necessary step for Vmn2r3 receptor trafficking and function. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, which is required for vesicular trafficking and scission. By inhibiting this process, the endocytic recycling of Vmn2r3 would be inhibited, reducing its functional expression on the cell surface. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein inhibits tyrosine kinases, which are involved in the phosphorylation of proteins that regulate endocytosis and trafficking; this would inhibit the recycling of Vmn2r3 to the cell surface. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is another V-ATPase inhibitor, which would lead to disrupted endosomal acidification, impairing the function of Vmn2r3 by inhibiting its trafficking to the plasma membrane. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin disrupts Golgi function, which would inhibit the post-translational modification and trafficking of Vmn2r3 to the cell surface, thereby inhibiting its function. | ||||||
Filipin III | 480-49-9 | sc-205323 sc-205323A | 500 µg 1 mg | $118.00 $148.00 | 26 | |
Filipin III disrupts cholesterol-rich lipid rafts, which are necessary for the proper localization and function of many receptors, potentially including Vmn2r3, thus inhibiting its function. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin polymerization, which would inhibit the cytoskeletal rearrangements required for Vmn2r3 trafficking and function on the cell surface. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which would inhibit intracellular transport processes essential for the trafficking and function of Vmn2r3. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Latrunculin B binds to actin monomers, preventing their polymerization. This would inhibit the proper localization of Vmn2r3 to the cell surface, thus inhibiting its function. | ||||||